SOFOSBUVIR
SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of genotype 1, 2,3 or 4 chronic hepatitis C virus (HCV)infectionas a component of a combination antiviral treatment regimen.-Sofosbuvir is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and pediatric patients aged 12 years and older. It is often used in combination with other antiviral medications for optimal efficacy. -Chronic hepatitis C virus (HCV) of genotype 1, 2,3 or 4.
-The dosage of sofosbuvir depends on various factors, including the genotype of the HCV virus, the patient's medical history, and whether it is used in combination with other medications. It is usually taken orally once daily with or without food. -Oral: 400mg once daily.
Sofosbuvir is contraindicated in patients with a known hypersensitivity to the drug or any of its components. It should not be used in combination with certain medications that may interact adversely with sofosbuvir, such as rifampin and St. John's wort.
Paediatric: Safety and efficacy for less than 18 years not yet established. Pregnancy: Category B. Lactation: No significant heath effect seen in animal model. Elderly: No dosage adjustment needed.
fatigue, headache, nausea, insomnia, itching, anemia, weakness, rash, decreased appetite, chills, flu-like illness, fever, diarrhea, joint pain, and irritability.
Sofosbuvir may interact with certain medications, including amiodarone, certain anticonvulsants, certain antiretroviral agents, and certain herbal supplements. It is important to inform the healthcare provider about all medications, supplements, and herbal products being taken to avoid potential interactions.
